Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Change in Accured Expenses for 8 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 32.09% year-over-year to $4.5 million, compared with a TTM value of -$15.3 million through Dec 2025, down 357.33%, and an annual FY2025 reading of -$15.3 million, down 357.33% over the prior year.
  • Change in Accured Expenses was $4.5 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$5.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.6 million in Q2 2021 and bottomed at -$9.4 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is $182800.0, with a median of -$81000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses soared 465.08% in 2021, then tumbled 2174.66% in 2025.
  • Year by year, Change in Accured Expenses stood at -$9.4 million in 2021, then skyrocketed by 178.73% to $7.4 million in 2022, then tumbled by 61.65% to $2.8 million in 2023, then surged by 130.15% to $6.6 million in 2024, then tumbled by 32.09% to $4.5 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ARCT at $4.5 million in Q4 2025, -$5.4 million in Q3 2025, and -$6.1 million in Q2 2025.